Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
Xu J, Wan R, Cai Y, Cai S, Wu L, Li B, Duan J, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Yu J, Yao S, Shen R, Wang Z, Wang J. Xu J, et al. Among authors: zhou t, zhou s, zhou c. Cancer Cell. 2024 Sep 9;42(9):1598-1613.e4. doi: 10.1016/j.ccell.2024.08.013. Cancer Cell. 2024. PMID: 39255777 Free article.
Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.
Yuan C, Huang M, Wang H, Jiang W, Su C, Zhou S. Yuan C, et al. Among authors: zhou s. Cancer Manag Res. 2022 Jan 26;14:377-386. doi: 10.2147/CMAR.S347547. eCollection 2022. Cancer Manag Res. 2022. PMID: 35115834 Free PMC article.
The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis.
Zhao Y, He J, Zhou S, Ning R, Zhao W, Wang H, Su C, Jiang W, Zhong X, Yu Q. Zhao Y, et al. Among authors: zhou s. Comput Math Methods Med. 2022 Sep 7;2022:1679191. doi: 10.1155/2022/1679191. eCollection 2022. Comput Math Methods Med. 2022. PMID: 36118825 Free PMC article.
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S, Tan L, Wang H, Su C, He J, Zeng A, Zhao Y, Yu Q. Chen S, et al. Among authors: zhou s. Front Immunol. 2022 Dec 7;13:1059995. doi: 10.3389/fimmu.2022.1059995. eCollection 2022. Front Immunol. 2022. PMID: 36569915 Free PMC article.
The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
Chen S, Mo W, Jiang W, Zhou S, Gan H, Yu Q. Chen S, et al. Among authors: zhou s. Front Immunol. 2023 Aug 8;14:1218258. doi: 10.3389/fimmu.2023.1218258. eCollection 2023. Front Immunol. 2023. PMID: 37614237 Free PMC article.
22,403 results
You have reached the last available page of results. Please see the User Guide for more information.